Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Prefrontal cortical dopamine (DA) regulates various executive cognitive functions, including attention and working memory. Efforts to enhance prefrontal-related cognition, which have focused on catecholaminergic stimulant drugs, have been unsatisfactory. Recently, the demonstration that a functional polymorphism in the catecholamine-O-methyltransferase (COMT) gene impacts prefrontal cognition raises the possibility of a novel pharmacological approach for the treatment of prefrontal lobe executive dysfunction. To explore in a proof of concept study the effects of tolcapone, a CNS penetrant specific COMT inhibitor, we performed a randomized, double blind, placebo controlled, and crossover design of this drug in normal subjects stratified by COMT (val158met) genotype. COMT enzyme activity was determined in peripheral blood. Forty-seven normal volunteers with no family history of psychiatric disorders underwent neuropsychological testing and 34 of those subjects underwent physiological measurement of prefrontal information processing assessed by blood oxygen level-dependent functional magnetic resonance imaging (fMRI). We found significant drug effects on measures of executive function and verbal episodic memory and a significant drug by genotype interaction on the latter, such that individuals with val/val genotypes improved, whereas individuals with met/met genotypes worsened on tolcapone. fMRI revealed a significant tolcapone-induced improvement in the efficiency of information processing in prefrontal cortex during a working memory test. This study demonstrates enhancement of prefrontal cortical function in normal human subjects with a nonstimulant drug having COMT inhibitory activity. Our results are consistent with data from animal studies and from computational models of the effects of selective enhancement of DA signaling in the prefrontal cortex.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increasing dopamine activity in the mPFC improved set-shifting in humans (Apud et al 2007).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Apud et al 2007
In the citing paper
“For example, increasing DA levels in individuals who have high baseline DA levels impairs cognitive performance, (perhaps pushing them over the peak of the inverted U curve) whereas improvements are noted in individuals with lower baseline levels (pushing them closer to the apex of the curve) (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007; Cools, Frank et al. 2009).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
In the citing paper
“Furthermore, increasing DA levels interacts with the COMT val158met SNP consistent with the putative inverted U model with met individuals demonstrating diminished cortical efficiency during tasks of cognitive control and val individuals demonstrating improvements (Mattay, Goldberg et al. 2003; Apud, Mattay et al. 2007).”
From Developmental imaging genetics: Linking dopamine function to adolescent behavior (2014) · cites this paper as Apud, Mattay et al. 2007
Citations
Cites
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,381 · cited 6×
“This genetic effect has been demonstrated in humans for performance on a variety of cognitive tests, such as working memory and executive function (Egan et al, 2001; Ho et al, 2005) as well as prefrontal physiology as assessed by functional magnetic resonance imaging (fMRI) (Egan et al, 2001;…”
BackgroundMethodInfluentialSelf-citationChen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675 · cited 3×
“COMT val158met (rs4680 G to A) genotyping was determined using Taqman 50-exonuclease allelic discrimination assay (Applied Biosystems, Foster City, CA) as described elsewhere (Chen et al, 2004).”
BackgroundMethodSelf-citationThe principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 2×
“There are also reports that COMT genotype affects function on declarative memory tests referable to processing in temporal lobe structures implicated in long-term memory (de Frias et al, 2004) Converging evidence from electrophysiological studies in experimental animals indicates that DA focuses and stabilizes prefron…”
BackgroundMendelian Proportions in a Mixed Population
Hardy, G. H. (1908) · Science · doi:10.1126/science.28.706.49 · Cited by 1,339
Männistö, P. T., & Kaakkola, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01423-6 · Cited by 1,068 · cited 2×
“0 h after administration of tolcapone and maximum inhibition of COMT activity in red blood cells is achieved between 1 and 4 h following administration of the drug (Jorga et al, 1999; Jorga, 1998; Mannisto and Kaakkola, 1999).”
BackgroundInfluentialMattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 9×
“In fact, the effects of amphetamine on prefrontal efficiency measured with fMRI (Mattay et al, 2003) were more noticeable in val/val individuals, a group with putatively higher COMT activity in the frontal cortex and, hence, relatively lower DLFPC synaptic DA concentrations.”
BackgroundMethodInfluentialSelf-citationGogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864 · cited 4×
“…release or metabolism, studies of COMT knock-out mice and of COMT inhibitors in rodents indicate that COMT has little impact on norepinephrine flux in prefrontal cortex, perhaps because of the abundance of functional norepinephrine transporters (Gogos et al, 1998; Tunbridge et al, 2004).”
BackgroundResultInfluentialAuditory Working Memory and Wisconsin Card Sorting Test Performance in Schizophrenia
Gold, J. M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830140071013 · Cited by 819 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal cortical contributions to working memory: evidence from event-related fMRI studies
D'Esposito, M., Postle, B. R., & Rypma, B. (2000) · Experimental Brain Research · doi:10.1007/s002210000395 · Cited by 794 · cited 2×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundPrefrontal neurons and the genetics of schizophrenia
Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 741 · cited 1×
“This drug by genotype effect is consistent with relatively lower prefrontal cortical DA signaling in these subjects and presumed benefit of enhanced prefrontal DA in this context (Mattay et al, 2003; Weinberger et al, 2001).”
BackgroundSelf-citationMorón, J. A., Brockington, A., Wise, R. A., Rocha, B. A., & Hope, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00389.2002 · Cited by 681 · cited 2×
“…480 7795, E-mail: weinberd@mail.nih.gov Neuropsychopharmacology (2007) 32, 1011–1020 & 2007 Nature Publishing Group All rights reserved 0893-133X/07 $30.00 www.neuropsychopharmacology.org functionally inconsequential (Gogos et al, 1998; Mazei et al, 2002; Moron et al, 2002; Tunbridge et al, 2004).”
BackgroundInfluentialGoldberg, T. E., Egan, M. F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, B. S., Goldman, D., & Weinberger, D. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.889 · Cited by 583 · cited 2×
“…genotype influences performance on cognitive tests of prefrontal cortex function such as working memory and executive function (Egan et al, 2001; Goldberg et al, 2003) as well as prefrontal efficiency as assessed by fMRI (Egan et al, 2001; Mattay et al, 2002, 2003), that genotype would interact…”
BackgroundMethodSelf-citationSesack, S. R., Hawrylak, V. A., Matus, C., Guido, M. A., & Levey, A. I. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02697.1998 · Cited by 582 · cited 2×
“In humans, COMT is found in high concentrations in the cortex relative to subcortical regions such as the striatum and amygdala (Lloyd et al, 1975; Matsumoto et al, 2003) consistent with the absence of functional DA transporters in cortical areas such as prefrontal cortex and hippocampus (Hall et al, 1999; Mazei et al…”
BackgroundCatechol-O-Methyl Transferase: Pharmacological Aspects and Physiological Role
Guldberg, H. C., & Marsden, C. A. (1975) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06681-5 · Cited by 554 · cited 1×
“In the last 30 years, a number of compounds with inhibitory activity on COMT were discovered (Guldberg and Marsden, 1975).”
BackgroundTunbridge, E. M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1124-04.2004 · Cited by 418 · cited 10×
“…release or metabolism, studies of COMT knock-out mice and of COMT inhibitors in rodents indicate that COMT has little impact on norepinephrine flux in prefrontal cortex, perhaps because of the abundance of functional norepinephrine transporters (Gogos et al, 1998; Tunbridge et al, 2004).”
BackgroundResultInfluentialDopaminergic modulation of cortical function in patients with Parkinson's disease
Mattay, V. S., Tessitore, A., Callicott, J. H., Bertolino, A., Goldberg, T. E., Chase, T. N., Hyde, T. M., & Weinberger, D. R. (2002) · Annals of Neurology · doi:10.1002/ana.10078 · Cited by 402 · cited 3×
“A similar effect of l-dopa therapy was found in patients with Parkinson’s disease undergoing fMRI during the same task (Mattay et al, 2002).”
BackgroundMethodSelf-citationThe neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd, K. G., Davidson, L., & Hornykiewicz, O. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30363-0 · Cited by 396 · cited 1×
“In humans, COMT is found in high concentrations in the cortex relative to subcortical regions such as the striatum and amygdala (Lloyd et al, 1975; Matsumoto et al, 2003) consistent with the absence of functional DA transporters in cortical areas such as prefrontal cortex and hippocampus (Hall et…”
BackgroundCools, R., Stefanova, E., Barker, R. A., Robbins, T. W., & Owen, A. M. (2002) · Brain · doi:10.1093/brain/awf052 · Cited by 396 · cited 2×
“Consistent with this basic evidence, neuroimaging studies with pharmacological manipulations in normal humans using indirect agonists such as amphetamine or with levodopa treatment in patients with Parkinson’s disease have demonstrated that increasing DA activity, to some extent, ‘focuses’ PFC activity during executiv…”
BackgroundKaroum, F., Chrapusta, S. J., & Egan, M. F. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63030972.x · Cited by 347
Self-citationEffects of dextroamphetamine on cognitive performance and cortical activation
Mattay, V. S., Callicott, J. H., Bertolino, A., Heaton, I., Frank, J. A., Coppola, R., Berman, K. F., Goldberg, T. E., & Weinberger, D. R. (2000) · NeuroImage · doi:10.1006/nimg.2000.0610 · Cited by 296 · cited 1×
“…as amphetamine or with levodopa treatment in patients with Parkinson’s disease have demonstrated that increasing DA activity, to some extent, ‘focuses’ PFC activity during executive cognition (ie it enhances prefrontal physiologic ‘efficiency’) (Cools et al, 2002; Mattay et al, 2000, 2002, 2003).”
BackgroundSelf-citationA comparison of rCBF patterns during letter and semantic fluency.
Gourovitch, M. L., Kirkby, B. S., Goldberg, T. E., Weinberger, D. R., Gold, J. M., Esposito, G., Van Horn, J. D., & Berman, K. F. (2000) · Neuropsychology · doi:10.1037//0894-4105.14.3.353 · Cited by 294 · cited 1×
“…to COMT genotype (notably, N Back, CPT, verbal memory, ID/ED), engage prefrontal cortical processes, and/or demonstrate a response to psychostimulant medication (notably verbal fluency, trail making and letter number span) (D’Esposito et al, 2000; Gold et al, 1997; Gourovitch et al, 2000).”
BackgroundSelf-citationHo, B. C., Wassink, T. H., O'Leary, D. S., Sheffield, V. C., & Andreasen, N. C. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001616 · Cited by 193 · cited 1×
“…has been demonstrated in humans for performance on a variety of cognitive tests, such as working memory and executive function (Egan et al, 2001; Ho et al, 2005) as well as prefrontal physiology as assessed by functional magnetic resonance imaging (fMRI) (Egan et al, 2001; Mattay et al, 2003).”
MethodCOMT Gene Polymorphism Is Associated with Declarative Memory in Adulthood and Old Age
de Frias, C. M., Annerbrink, K., Westberg, L., Eriksson, E., Adolfsson, R., & Nilsson, L.-G. (2004) · Behavior Genetics · doi:10.1023/b:bege.0000038491.06972.8c · Cited by 162 · cited 4×
“Furthermore, COMT genotype effects on a variant of an episodic memory task have been described in an aging adult population ( de Frias et al, 2004 ).”
BackgroundInfluentialMatsumoto, M., Weickert, C. S., Beltaifa, S., Kolachana, B. S., Chen, J., Hyde, T. M., Herman, M. M., Weinberger, D. R., & Kleinman, J. E. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300218 · Cited by 156 · cited 2×
“Regarding the latter possibility, in humans COMT is known to be abundantly expressed in medial temporal lobe regions, especially the hippocampus (Matsumoto et al, 2003).”
BackgroundSelf-citationSyv??nen, A.-C., Tilgmann, C., Rhine, J., & Ulmanen, I. (1997) · Pharmacogenetics · doi:10.1097/00008571-199702000-00009 · Cited by 151 · cited 2×
“Previous studies of COMT activity in human red blood cells (Syvanen et al, 1997) and in human brain (Chen et al, 2004) have also indicated that COMT val/met genotype affects COMT activity, but the difference between homozygote genotypes is less than that associated with higher doses of tolcapone…”
BackgroundResultMazei‐Robison, M. S., Pluto, C. P., Kirkbride, B., & Pehek, E. A. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02542-8 · Cited by 151 · cited 6×
“functionally inconsequential (Gogos et al, 1998; Mazei et al, 2002; Moron et al, 2002; Tunbridge et al, 2004).”
BackgroundResultInfluentialHall, H., Halldin, C., Guilloteau, D., Chalon, S., Emond, P., Besnard, J., Farde, L., & Sedvall, G. (1999) · NeuroImage · doi:10.1006/nimg.1998.0366 · Cited by 137 · cited 1×
“…to subcortical regions such as the striatum and amygdala (Lloyd et al, 1975; Matsumoto et al, 2003) consistent with the absence of functional DA transporters in cortical areas such as prefrontal cortex and hippocampus (Hall et al, 1999; Mazei et al, 2002; Pozzi et al, 1994; Sesack et al, 1998).”
BackgroundPozzi, L., Invernizzi, R., Cervo, L., Vallebuona, F., & Samanin, R. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63010195.x · Cited by 113 · cited 2×
“In humans, COMT is found in high concentrations in the cortex relative to subcortical regions such as the striatum and amygdala (Lloyd et al, 1975; Matsumoto et al, 2003) consistent with the absence of functional DA transporters in cortical areas such as prefrontal cortex and hippocampus (Hall et al, 1999; Mazei et al…”
BackgroundCognitive improvement during Tolcapone treatment in Parkinson's disease
Gasparini, M., Fabrizio, E., Bonifati, V., & Meco, G. (1997) · Journal of Neural Transmission · doi:10.1007/bf01285556 · Cited by 111 · cited 3×
“In patients with Parkinson’s disease, tolcapone was reported to improve function in attentional tasks, auditory verbal short-term memory, visuo-spatial recall, and constructional praxia, changes that are not typically associated with levodopa therapy alone (Gasparini et al, 1997).”
BackgroundInfluential18 F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
Ceravolo, R., Piccini, P. P., Bailey, D. L., Jorga, K. M., Bryson, H., & Brooks, D. J. (2001) · Synapse · doi:10.1002/syn.10034 · Cited by 107 · cited 2×
“…inhibit peripheral COMT with greater potency than the enzyme present in the central nervous system, tolcapone does penetrate the blood–brain barrier (Ceravolo et al, 2002) and inhibits brain COMT activity in vivo with an inhibitory dose 50 (ID50) value of 26–28 mg/kg in the rodent (Da Prada et al,…”
BackgroundMetabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase
Jorga, K. M., Fotteler, B., Heizmann, P., & Gasser, R. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00036.x · Cited by 94 · cited 1×
“Prior studies have shown that plasma levels peak about 1.5–2.0 h after administration of tolcapone and maximum inhibition of COMT activity in red blood cells is achieved between 1 and 4 h following administration of the drug (Jorga et al, 1999; Jorga, 1998; Mannisto and Kaakkola, 1999).”
BackgroundInfluentialZürcher, G., Hh, K., Kettler, R., Borgulya, J., Bonetti, E. P., Eigenmann, R., & Prada, M. D. (1990) · PubMed · Cited by 87
Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues
Zürcher, G., Colzi, A., & Prada, M. D. (1990) · Springer eBooks · doi:10.1007/978-3-7091-9113-2_51 · Cited by 75 · cited 1×
“Among them, tolcapone (Zurcher et al, 1990a, b) proved to be the most potent in vitro.”
BackgroundLiljequist, R., Haapalinna, A., Ahlander, M., Li, Y. H., & Männistö, P. T. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)80989-8 · Cited by 69
Forsberg, M., Lehtonen, M., Heikkinen, M., Savolainen, J., Järvinen, T., & Männistö, P. T. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.042846 · Cited by 63 · cited 2×
“Neuropsychopharmacology animals showed that tolcapone has a 60% brain bioavailability reaching a brain concentration to 1% of plasma concentrations (Forsberg et al, 2003).”
BackgroundLi, Y.-H., Wirth, T., Huotari, M., Laitinen, K. S. M., MacDonald, E., & Männistö, P. T. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00524-x · Cited by 40 · cited 2×
“Moreover, because COMT does not appear to significantly impact extracellular DA levels in the rat striatum (Gogos et al, 1998; Li et al, 1998; Tunbridge et al, 2004) it might be expected that these effects would occur without psychostimulant properties and abuse”
BackgroundJorga, K. M. (1998) · Neurology · doi:10.1212/wnl.50.5_suppl_5.s31 · Cited by 37
Prada, M. D., Zürcher, G., Kettler, R., & Colzi, A. (1991) · Advances in behavioral biology · doi:10.1007/978-1-4684-5871-8_78 · Cited by 27 · cited 2×
“…greater potency than the enzyme present in the central nervous system, tolcapone does penetrate the blood–brain barrier (Ceravolo et al, 2002) and inhibits brain COMT activity in vivo with an inhibitory dose 50 (ID50) value of 26–28 mg/kg in the rodent (Da Prada et al, 1991; Zurcher et al, 1991).”
Background
Research works printed but not linked: 3
- McNair D, Lorr M (1981). ITS Manual for the Profile of Mood States. Multi-health System, Inc.: San Diego, CA.
- Weinberg W (1908). ber den Nachweis der Vererbung beim Menschen. Jahresh Ver Vaterl Naturk Württemb 64: 368–382.
- Zurcher G, Dingemanse J, Da Prada M (1991). Ro-40-7592, A Potent Inhibitor of Extracerebral and Brain Catechol-O-methyltransferase: Preclinical and Clinical Findings. John Libbey SRL: Rome.
Cited by
Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control
Cools, R., & D'Esposito, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.028 · Cited by 1,673
The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation
Robbins, T. W., & Arnsten, A. F. T. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135535 · Cited by 957
“…role of DA in intradimensional set shifting in primates has been supported by a recent pharmacological study of the effects of the COMT inhibitor tolcapone in humans: This drug, which may enhance PFC DA function , improved intradimensional shift performance in volunteers (Apud et al. 2007).”
BackgroundDurstewitz, D., & Seamans, J. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.015 · Cited by 586
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
“In addition, a small study found atomoxetine to improve working memory-related PFC activity in schizophrenia (Friedman et al, 2008), and inhibition of COMT with tolcapone improves cortical activity and working memory performance in healthy adults, dependent on COMT genotype (Apud et al, 2007).”
Background
Metadata
- Authors
- Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., Goldberg, T. E., & Weinberger, D. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Weinberger, Daniel R
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2006-10-25
- Volume
- 32
- Issue
- 5
- Pages
- 1011-1020
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2123236884
- Cited by
- 242
- References
- 39
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 9 · 2023: 4 · 2022: 19 · 2021: 9 · 2020: 12 · 2019: 4 · 2018: 7 · 2017: 12 · 2016: 14 · 2015: 13 · 2014: 6 · 2013: 25 · 2012: 18
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- tolcapone, COMT inhibition, COMT Val158Met polymorphism, prefrontal cortex, executive function, working memory, verbal episodic memory, dopamine signaling
- MeSH terms
- Tolcapone, Adult, Benzophenones, Brain Mapping, Catechol O-Methyltransferase, Cognition, Double-Blind Method, Enzyme Inhibitors, Female, Genotype, Humans, Magnetic Resonance Imaging, Male, Memory, Middle Aged, Neuropsychological Tests, Nitrophenols, Placebos, Reference Values, Treatment Outcome, Prefrontal Cortex, Cross-Over Studies, Amino Acid Substitution, Catechol O-Methyltransferase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.